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Introduction  
The animal-type rhodopsins are themselves G protein-coupled receptors. Generally the 
conformational changes upon light absorption, facilitate the coupling with a certain type of 
trimeric G-proteins which regulate metabolic cascades in the cell. Although microbial-type 
rhodopsins are also 7-TM retinal-binding proteins, they show no sequence homology to animal-
type rhodopsins. 
 Channelrhodopsins (ChR) are combined structure of a photoreceptor and an ion channel 
of which gating is regulated by light (Nagel et al., 2002, 2003). As all other microbial-type 
rhodopsins, ChRs undergo a cyclic sequence of reactions in result of photoisomerization of all-
trans retinal to 13-cis retinal configuration (Berndt et al., 2010). There are at least 2 
distinguishable photocycle for ChR1 and 2 (dark-adapted and light-adapted). In this model, ChR 
exists in two dark states, D1 and D2, that photoisomerized to be the conductive states O1 and O2, 
respectively (Hegemann et al., 2005). For ChR2, during blue light irradiation, the photocurrent 
peaks almost instantaneously, but desensitizes rapidly to a steady state within several tens of 
milliseconds. It takes several tens of seconds for full recovery from desensitization (Nagel et al., 
2003; Ishizuka et al., 2006; Yawo et al., 2013). The prominent desensitization of the ChR2 
photocurrent limits its application for repetitive stimulation at high frequency. A better 
understanding of detailed biophysical knowledge of ChRs would guide Optogenetics in 
generation of ChR variants with novel function related to spectrum, selectivity and kinetic. The 
photocurrent kinetics in combination with the molecular modifications would give us insights of 
the relatively fast molecular dynamics and the molecular determinates involved in it. In the 
present study, we compared the spectral sensitivity between desensitized and non-desensitized 
fractions of the chimeric ChRs between ChR1 and -2. It is suggested that the structures in TM5 
and 7 are involved in the spectral transition during desensitization. 
Materials 
Plasmid Construction: The amino acid sequences of the ChR1 and 2 were divided into 
seven transmembrane domains (TMD) so that each TMD contains a transmembrane helix 
practically. These segments are referred to (from N-terminal to C-terminal) as “A,” “B,” “C,” “D,” 
“E,” “F,” and “G” for ChR1. The homologous counterparts of ChR2 are referred to as “a,” “b,” 
“c,” “d,” “e,” “f,” and “g.” The N-terminal domain of ChR2 was replaced in order with the 
corresponding counterpart of ChR1 and we prepared 6 chimeras. The seventh domain (TMD7) 
was additionally subdivided into two subdomains to prepare ChR1-fg1 (ABCDEfg1G2) and 
ChR1-fg2 (ABCDEfG1g2).  
Cell culture and Transfection: The electrophysiological assays of ChR variants were 
made using ND 7/23 cells, hybrid cell lines derived from neonatal rat dorsal root ganglia neurons 
fused with the mouse neuroblastoma (Watanabe et al., 2016). The day before transfection, 5  
105 per ml ND 7/23 cells were seeded on the collagen-coated coverslips in a 4-well plate. 
Effectene Transfection Reagent (ETR, Qiagen, Tokyo, Japan) was used to transfect the vector 
plasmids to the ND 7/23 cells according the manufacture protocol. 
Electrophysiology and Optics: All experiments were carried out at room temperature (23 
± 2 °C). Photocurrents were recorded using an EPC-8 amplifier (HEKA Electronic, Lambrecht, 
Germany) under a whole-cell patch clamp configuration. To investigate the action spectrum, 
irradiation was carried out using a SpectraX light engine (Lumencor Inc., Beaverton, OR) 
controlled by computer software (pCLAMP 10.3, Molecular Devices) at wavelengths (nm, >90% 
of the maximum): 390 ± 18, 438 ± 24, 475 ± 28, 513 ± 17, 549 ± 15, 575 ± 25 and 632 ± 22. 
Two short pulses of light (100 ms) were applied before and after irradiation of 1-s blue light (475 
± 28 nm, 0.92 mW/mm2). Each irradiation protocol was applied at every 60 s to accomplish the 
full recovery from the desensitization. 
Statistical analysis: All data in the text, figures and tables are expressed as mean ± SEM 
and were evaluated with Wilcoxon signed rank test for statistical significance unless otherwise 
noted. It was judged as statistically insignificant when P > 0.05. 
Results 
Desensitizing and non-desensitizing components of ChR2 photocurrent: To distinguish 
the desensitizing component which is generated by the dark-adapted photocycle from the non-
desensitizing component which is generated by the light-adapted photocycle, two test pulses of 
light (100 ms) were applied to measure the photocurrents immediately before and after 
irradiation of 1-s blue light illumination (475 ± 28 nm, 0.92 mWmm-2) which completely 
desensitized the photocurrent. The difference of these photocurrents represented the 
desensitizing component of photocurrent (Ides). The peak Ides was measured for each wavelength 
(Fig. 9B-9F). Similarly, the steady-state photocurrent at the end of second 100 ms pulse was 
measured for each wavelength to evaluate the action spectrum of the non-desensitizing 
component (Inon) (Fig. 9B-9F).  The relative sensitivity to 475 nm was calculated for each 
wavelength and expressed as R(390/475), R(438/475), R(513/475), R(549/475) and R(575/475), 
respectively (Table 1). 
Desensitizing and non-desensitizing components for ChR1: The spectral sensitivity of Ides 
could not be investigated because of the low amplitude of the subtracted component. Replacing 
TMD6 of ChR1 by its counterpart from ChR2 (ChR1-f) improves the amplitude (Wen, et al., 
2012). So the Ides and Inon of ChR1-f was thus measured for each wavelength (Fig. 11B-G), and 
its action spectrum was obtained (Fig. 12). The action spectrum of ChR1-f was 10-20 nm blue-
shifted by desensitization. 
Desensitizing and non-desensitizing components for Chimeric ChRs: The above spectral 
transition would be attributed to the structural difference of apoproteins between ChR1 and -2. 
To test this, we examined the ChR1 and 2 chimeras. The spectral difference between Ides an Inon 
was variable from one chimera to another (Table 1). For example the R(438/475) of Inon was 
significantly larger than that of Ides for ChR-Abcdefg, ChR-ABcdefg and ChR-ABCDefg whereas 
it was significantly smaller than that of Ides for ChR-ABCDEfg. In the middle of the TM7 of 
ChR1, Lys296 is where the retinal is covalently binding. We subdivided the domain containing 
TMD7 (G) into two subdomains to get the ChR1-fg1 or ChR1-fg2. the action spectra of Ides and 
Inon were again obtained (Fig. 16A and 16B). The desensitization-dependent spectral transition of 
ChR1-fg1 was almost similar to that of ChR-ABCDEfg. On the other hand that of ChR1-fg2 was 
similar to that of ChR1-f.  
Discussion  
The present study is the first report that differentiated two components of ChR 
photocurrent, Ides and Inon and revealed that the desensitization was accompanied with the change 
of action spectrum. We found that ChR2 and ChR1-f were different in the desensitization-
dependent spectral transition. In the case of ChR2, the action spectrum of Inon was broader than 
that of Ides in both bands between 390 and 475 nm and between 475 and 575 nm with significant 
increase of R(438/475) and R(513/475). On the other hand, in the case of ChR1-f, the action 
spectrum of Inon was blue-shifted from that of Ides with significant reduction of R(513/475). To 
find the structures involved in this difference, the chimeric ChRs, in which N-terminal segments 
of ChR2 were replaced by the counterparts of ChR1, were examined. Result showed that TMD5 
and TMD7 is thus suggested to be the structures involved in the desensitization-dependent 
transition of action spectrum. The exchange of G1 with the counterpart of ChR2 (g1) abolished 
the desensitization-dependent blue shift of action spectrum. Therefore, the structural difference 
between G1 and g1 is suggested to be involved in the desensitization-dependent transition of 
action spectrum. Indeed, chimeras such as ChR-ABCdefg (ChRFR), ChR-ABCDEfg (ChRWR, 
ChEF, C1C2) and ChR1-fg2 (ChRGR) and their mutants have been frequently used in the various 
experimental systems as efficient optogenetic actuators (Wang et al., 2009; Wen et al., 2010; Lin 
et al., 2009; Wang et al., 2012; Umeda et al., 2013; Kimura et al., 2013; Egawa et al., 2013; 
Asano et al., 2015; Notomi et al., 2015; Umeda et al., 2016).  
 
 
